Changes in thyroid fine needle aspiration practice during the COVID-19 pandemic

Duccio Rossi¹ | Alessia Belotti² | Clementina di Tonno³ | Valeria Midolo³ | Fausto Antonio Maffini⁴ | Luca Nicosia⁵ | Elvio De Fiori⁶ | Giovanni Mauri⁷,⁸

¹Postgraduate School of Radiodiagnostics, Università Degli Studi di Milano, Milan, Italy
²Postgraduate School of Pathology, Università Degli Studi di Milano, Milan, Italy
³Division of Cytopathology, IEO, European Institute of Oncology IRCCS, Milan, Italy
⁴Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy
⁵Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
⁶Department of Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
⁷Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy
⁸Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy

Correspondence
Duccio Rossi, Postgraduate School of Radiodiagnostics, Università Degli Studi di Milano, Via Festa del Perdono 7, Milan 20122, Italy.
Email: duccio.rossi@unimi.it

Abstract
Purpose: To investigate the diagnostic accuracy of a different sample preparation protocol for fine needle aspiration cytology (FNAC) of thyroid nodules established during the COVID-19 pandemic.
Methods: From April 2020, conventional smears during FNAC were ceased according to World Health Organization recommendations due to the increased infection risk for operators, and a new protocol using only liquid-based cytology (LBC) was adopted. FNACs performed between April and July 2020 (COVID-19 group) were retrospectively compared with those from December 2019 through March 2020 (Pre-COVID-19 group). The distribution of diagnoses based on SIAPEC-IAP categories and the concordance between cytological and histological results were compared using the chi-squared test.
Results: Categories based on FNAC for 90 and 82 thyroid nodules in the Pre-COVID-19 and COVID-19 groups showed no significant difference in distribution (P = .081), with the following respective cases (and percentages): TIR1, 7 (8%) and 8 (10%); TIR1C, 0 (0%) and 6 (7%); TIR2, 59 (66%) and 55 (67%); TIR3A, 8 (9%) and 5 (6%); TIR3B, 1 (1%) and 2 (3%); TIR4, 5 (6%) and 1 (1%); and TIR5, 10 (12%) and 5 (7%). Among patients with potentially malignant lesions, surgery was performed for 12/16 (75%) nodules in the Pre-COVID-19 and 7/8 (88%) nodules in the COVID-19 groups, with no significant differences between cytological and histological diagnoses (P = .931).
Conclusion: The new LBC-only protocol provided similar diagnostic accuracy in comparison with conventional smears, and can be effectively applied during a viral pandemic improving operator safety.

KEYWORDS
COVID-19, cytology, fine needle aspiration, surgery, thyroid
1 | INTRODUCTION

Thyroid nodules are very common in the general population (being detected at rates of up to 65%), especially in women, and thyroid cancer is the most common neoplasm of the endocrine system, accounting for about 90% of cases.

Most thyroid lesions are benign and the malignant ones account for less than 10%, being usually well-differentiated neoplasms with a slow growth and excellent outcomes. Papillary carcinoma is the most common form of well-differentiated thyroid cancer.

The initial evaluation of a patient with thyroid nodules includes a full laboratory workup and ultrasound (US) evaluation with or without fine needle aspiration cytology (FNAC).

FNAC is a cost-effective and useful method for assessing the nature of thyroid nodular lesions characterised by high sensitivity and many advantages such as ready-to-use equipment for a high-quality product, a low rate of complications, and good patient tolerability.

In most centres, the standard protocol for FNAC slide production consists of preparing thin smears that are rapidly air-dried and/or fixed in 95% ethanol solution. Liquid-based methods for cytology (LBC) have been reported to provide good diagnostic accuracy and are becoming routinely used, either alone or in combination with standard cytological preparation, especially to standardise the pre-analytical procedures that are needed to perform immunocytochemistry (ICC) or molecular tests. Even if there is still some debate regarding the routine application of LBC in thyroid FNAC, it should be noted that this method carries the not negligible advantage of also reducing the risk of aerosol diffusion of potentially infected material, which could be of particular value during a pandemic.

By April 2020, the coronavirus disease 2019 (COVID-19) which was firstly reported in Wuhan, China, in December 2019, had dramatically spread in northern Italy. By then, stricter measures to address its specific biological risk in laboratories were being recommended. Due to the potential presence of the virus in histological and cytological specimens, the World Health Organization (WHO) advised that specimen processing should occur in accordance to biosafety level 2 guidelines. Only tissue samples completely fixed in formalin (after 24 hours at room temperature) or in ethanol 95% were to be considered not a microbiological risk. COVID-19 virus was identified mainly in samples of lung and oral origin, rarely in other biomaterials such as blood and faecal material.

A recent work published at our institution demonstrated the presence of the virus even in the normal salivary gland samples using a real-time PCR-based assay. This result provided important information regarding possible infection sites or virus reservoirs and highlighted the need for proper fixation and handling prior to sample processing.

Moreover, transmission of coronaviruses from contaminated inert surfaces was postulated, including self-inoculation of mucous membranes of the nose, eyes, or mouth. According to a recent review article, the Severe Acute Respiratory Syndrome Coronavirus-2 virus (SARS-CoV-2) can last on different surfaces between hours and a few days, though a rapid virus inactivation is possible using commonly available chemicals and biocides on dry surfaces. However, at our institution, from April 2020 a change in the FNAC protocol was decided, avoiding both air-dried and alcohol-fixed slides. To avoid potentially infectious aerosol formation, all biological material must be fixed in an alcohol-based fixative solution. The adoption of LBC with a ThinPrep® automated system was decided according to our security criteria.

The aim of this work is to report the diagnostic accuracy of this new sample preparation protocol for FNAC of thyroid nodules established during the COVID-19 pandemic and to compare it with the diagnostic accuracy of the previously established standard protocol.

2 | METHODS

Approval for this retrospective study was obtained from our institution’s Ethics Committee and patients’ informed consent was waived. All thyroid US-guided FNACs for suspicious lesions performed between December 2019 and July 2020 at our institution were retrospectively analysed.

From the 4th of April, air-dried or alcohol-fixed slides were no longer used at our institution being high in risk of infectious aerosol formation while performing all the cyto-preparatory steps. Thus, we consider the 4th of April as the watershed day between the old and new protocols, dividing patients into two groups according to a specific time-based distinction labelled “Pre-COVID-19” (3 December 2019–3 April 2020) and “COVID-19” (4 April 2020–31 July 2020).

Cytological characterisation of lesions was reported, according to the joint classification of the Italian Society for Anatomic Pathology and Cytology with the Italian Division of the International Academy of Pathology (SIAPEC-IAP), as TIR1 (Inadequate), TIR1C (Inadequate-cystic), TIR2 (Benign), TIR3A (Indeterminate lesion with low risk of malignancy), TIR3B (Indeterminate lesion with high risk of malignancy), TIR4 (Suspicious for malignancy), and TIR5 (Malignant). Surgery was performed when high-risk or malignant lesions (TIR3B, TIR4, TIR5) were detected. The final diagnosis on histopathological reports was recorded when surgery was carried out at our institution.

All FNAC procedures were US-guided. Following identification of the lesion by ultrasonography and skin disinfection with alcohol, a 25-gauge needle was inserted into the desired nodule with the no-aspiration technique, according to which the needle was moved in different directions for a few seconds allowing material to enter it by capillary action. In the Pre-COVID-19 period, the needle content was expelled onto previously labelled slides and the smear was simply prepared by touching the second slide to the surface and separating them again. One set of slides was placed in the holder containing 95% alcohol solution while another set was left to air-dry. Another tissue sample was then performed on the desired nodule using a 22-gauge needle connected to a 20-mL syringe with the aspiration technique, according to which the negative pressure created by the pulling back of the syringe plunger was useful to collect cells into the cutting edge of the needle. The material was immediately rinsed into a ready-to-use ThinPrep CytoLyt® (Hologic Corporation).
alcohol-based fixative solution following the LBC method. The slide containers, labelled with the patient data, were sent to the cytology laboratory, along with a complete Cytopathology Requisition Form, including pertinent patient history.

During the COVID-19 period, in addition to the use of personal protective equipment including FFP2 or FFP3 masks, protective glasses and gloves, air-dried or alcohol-fixed slides and all air-dried handling materials were avoided and only the ThinPrep CytoLyt solution and LBC method were adopted. The ThinPrep CytoLyt solution was used to maximise the reduction in contamination risk without the need of further material handling after the FNA procedure. Therefore, the adoption of the CytoLyt solution and the LBC method allowed for both optimal morphological tissue preservation and reduction in the aerosol and droplet formation during conventional slide preparation.

According to this new protocol, the material was directly processed in the Cytopathology Laboratory, in a dedicated high-level biosafe hood as specified below:

1. The cytological specimen was put in a PreservCyt® solution vial and allowed to stand for at least 15 minutes (this step is fundamental to guaranteeing the complete SARS-CoV-2 virus inactivation, as instructed in the Technical Bulletin issued by the production house).
2. If the material in the vial appeared strongly turbid or bloody, it was washed with acetic acid and CytoLyt solutions before being prepared for the ThinPrep slides and run on a ThinPrep 5000 processor. If the specimen appeared clear, the ThinPrep slides were directly prepared and run on a ThinPrep 5000 processor.

2.1 | Data analysis

The distribution of the diagnostic categories between the Pre-COVID-19 and COVID-19 group was evaluated. When considering high-risk or malignant lesions, we also evaluated the accuracy and reliability of the Pre-COVID-19 and COVID-19 protocols using subsequent diagnosis on surgical specimens as reference when available.

Continuous data are reported as median values and ranges. Categorical data are reported as counts and percentages. Pearson’s chi-squared test was used to assess the distribution of the diagnostic categories between the two groups and to evaluate the agreement of cytological and histological diagnoses of potentially malignant lesions between the two methods. P values less than .05 were considered statistically significant. All data were collected and analysed on a Microsoft Excel spreadsheet.

3 | RESULTS

During the Pre-COVID-19 period 90 FNAC thyroid procedures were performed on 88 patients, compared with 82 procedures on 81 patients conducted during the COVID-19 period.

| TABLE 1 Distribution of diagnostic categories between the Pre-COVID-19 group (n = 90) and the COVID-19 group (n = 82) |
|-------------------------------------------------|-------------------------------------------------|
| **FNAC diagnoses** | **Pre-COVID-19 (n = 90)** | **COVID-19 (n = 82)** |
| TIR1 | 7 (8%) | 8 (10%) |
| TIR1C | 0 (0%) | 6 (7%) |
| TIR2 | 59 (66%) | 55 (67%) |
| TIR3A | 8 (9%) | 5 (6%) |
| TIR3B | 1 (1%) | 2 (2%) |
| TIR4 | 5 (6%) | 1 (1%) |
| TIR5 | 10 (11%) | 5 (6%) |
| P value | <.05 | .081 |

*Chi-squared test. Abbreviations: FNAC, fine needle aspiration cytology; TIR1, Inadequate; TIR1C, Inadequate-cystic; TIR2, Benign; TIR3A, Indeterminate lesion with low risk of malignancy; TIR3B, Indeterminate lesion with high risk of malignancy; TIR4, Suspicious for malignancy; TIR5, Malignant.

Patients’ average age was 57 years for the Pre-COVID-19 group and 53 for the COVID-19 group (range 22-81 years and 24-78 years, respectively). SIAPEC-IAP classification for samples in the Pre-COVID-19 group and COVID-19 group, respectively, were as follows: TIR1 in 7/90 (8%) and 8/82 (10%), TIR1C in 0/90 (0%) and 6/82 (7%), TIR2 in 59/90 (66%) and 55/82 (67%), TIR3A 8/90 (9%) and 5/82 (6%), TIR3B 1/90 (1%) and 2/82 (3%), TIR4 5/90 (6%) and 1/82 (1%), TIR5 10/90 (12%) and 5/82 (7%). No statistically significant difference was found in the distribution of cases among diagnostic categories (P = .081; Table 1). Among the high-risk patients (TIR3, TIR4, TIR5), 12/16 (75%) in the Pre-COVID-19 group and 7/8 (88%) in the COVID group underwent surgery at our institution, and no statistically significant difference was found between the two groups in terms of agreement between cytological and histological diagnoses of potentially malignant lesions (P = .931) (Table 2).

4 | DISCUSSION

US-guided FNAC has an essential role in the diagnostic pathway of thyroid nodules especially for its availability, rapidity, cost-effectiveness, and low level of associated procedural risks.

Air-dried slides with Romanowsky stain (Diff-Quik, May-Grünwald-Giemsa) usually represent a rapid and useful method to enhance pleomorphism and distinguish extracellular from intracytoplasmic material allowing good definition of the cell outline and cytoplasmic contents, whereas alcohol-fixed slides with Papanicolaou (Pap) stain allow a clearer visualisation of the cellular morphology and nuclear features.

However, the extraordinary COVID-19 emergency forced us to rethink the organisation and practices of FNAC considering that, according to recommendations of the WHO and other international organisations, the slide preparation could be dangerous because of the potentially infectious material. 15, 16
The aim of our work was to show the preliminary results of FNAC performed by using exclusively an LBC method that differs from the traditional one based on the preparation of cytological smears (CSs).

The overall number of thyroid FNAC procedures during the COVID-19 period was slightly lower compared to that of the Pre-COVID-19 period (82 vs 90, respectively), clearly related to the restrictions imposed by the Italian Government.

Our results showed no significant difference between the two types of procedures. Occasionally, more patients with purely cystic nodules presented during the COVID-19 period and this could explain the relatively higher proportion of TIR1C samples in this group. In this case, the final diagnosis of completely cystic nodule was made through the correlation of cytological and radiological features. However, even accounting for the higher number of patients with purely cystic nodules in the COVID-19 group, no statistically significant difference in the distribution of diagnostic categories between the two groups was found (P = .081). Also, for lesions suggestive of malignancy (TIR3B, TIR4 and TIR5), there was no statistically significant difference in the agreement between cytological and histological results for both protocols (P = .931).

The LBC method differs from the traditional one for a distinctive fixative method without a staining process that potentially removes diagnostic features as necrotic debris or colloid. The use of LBC-only versus CSs for thyroid FNA specimens is a long-standing dispute, especially because cytopathologists have always used CS slides and therefore are more used to the cytomorphological features of thyroid lesions.8-11 Recent studies demonstrated that an LBC-only method performs better than CS in terms of sample adequacy and it is almost the same in terms of sensitivity and specificity.26 The main advantages of LBC consist of its simple handling, excellent storage of the material,9,27 and faster microscopic examination of the samples as the cells are concentrated in a limited area and no air-drying artifacts are present.28 However, whereas the FNAC diagnosis of thyroid nodules is based on the observation of how the cells are clustered and on background materials such as colloid, the LBC method causes disruption of cell clusters, colloid fragmentation, and removal of background material. This is more evident for papillary lesions in which intranuclear pseudoinclusions, frequently indicative of malignancy, are less clear in LBC than in CSs. On the other hand, other characteristics of benign follicular lesions such as macrofollicular architecture are similar in both methods.26 However, as recently showed by Straccia et al29 in a paper where an LBC protocol similar to ours was adopted for the evaluation of all cytological samples, the morphological details and quality of the cellular component can be effectively preserved to achieve good diagnostic efficacy.

In the future, another approach, based on cytolgy combined with molecular testing on an LBC method, could improve the diagnosis of indeterminate FNAs, still avoiding the use of CSs.30-32

Our study has some limitations, mainly its retrospective nature and the fact that from a pathologist’s perspective, common Papanicolaou and Romanowsky stains on CSs are still used in a complementary fashion and currently represent the mainstay in the approach to the FNAC diagnosis.8 However, our approach, developed in a case of extreme emergency, suggests the reliability of an LBC method in terms of diagnosis and safety for healthcare workers.

## 5 | CONCLUSIONS

As the COVID-19 pandemic is still ongoing and vaccines, social-distancing, and contact prevention hold a crucial role in controlling the disease, the routine application of LBC to thyroid FNAC increases the safety of procedures without compromising diagnostic accuracy. Thus, our work supports a larger application of LBC, which could be particularly useful in case of a viral pandemic, being a reliable procedure while reducing the risk of viral spread.

## ACKNOWLEDGMENTS

The authors wish to thank the cyto-technicians and cyto-screeners for their work.

## CONFLICT OF INTEREST

The authors declare there are no conflicts of interest.

## AUTHOR CONTRIBUTIONS

DR, AB, C.d.T., VM, FAM, LN, E.d.F., G. M. contributed to the design and implementation of the research and to the writing of the manuscript. All authors have read and agreed to the published version of the manuscript.

## ETHICAL APPROVAL

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

## INFORMED CONSENT

Informed consent was obtained from all individual participants included in the study.

---

**TABLE 2** Comparison of cytological and histological diagnoses for potentially malignant lesions (TIR3B, TIR4, TIR5) in patients of the Pre-COVID-19 (n = 12/16; 75%) and COVID-19 groups (n = 7/8; 88%) who underwent surgery at our institution.

| Cytology | Pre-COVID-19 (n = 12) | COVID-19 (n = 7) |
|----------|----------------------|-----------------|
|          | Benign   | Carcinoma | Benign | Carcinoma |
| TIR3B    | 0 (100%) | 0        | 2 (100%) | 0        |
| TIR4     | 1 (100%) | 0 (0%)   | 0       | 1 (20%)  |
| TIR5     | 0        | 9 (82%)  | 0       | 4 (80%)  |
| \( P \text{ value} \) | \( <.05 \) | \( =.931^a \) | \( =.931 \) | \( =.931^a \) |

\( \text{Abbreviations: TIR3B, Indeterminate lesion with high risk of malignancy; TIR4, Suspicious for malignancy; TIR5, Malignant.} \)

\( ^a \text{Chi-squared test.} \)
REFERENCES

1. Paschou S, Vryonidou A, Goulis DG. Thyroid nodules: a guide to assessment, treatment and follow-up. Maturitas. 2017;96:1-9. https://doi.org/10.1016/j.maturitas.2016.11.002
2. Dal Maso L, Lise M, Zambon P, et al. Incidence of thyroid cancer in Italy, 1991–2005: time trends and age-period-cohort effects. Ann Oncol. 2011;22(4):957-963. https://doi.org/10.1093/annonc/mdq467
3. Morris LGT, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer due to the influence of access to care. Thyroid. 2013;23(7):885-891. https://doi.org/10.1089/thy.2012.0045
4. Smallridge RC, Ain KB, Asa SL, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104-1139. https://doi.org/10.1080/10407790.2012.03002
5. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045. https://doi.org/10.1136/bmj.g3045
6. Sheikh FA, Tinkoff GH, Kline TS, Neal HS. Final diagnosis by fine-needle aspiration biopsy for definitive operation in breast cancer. Am J Surg. 1987;154(5):470-474. https://doi.org/10.1016/0002-9610(87)90254-6
7. Ocjan G, Chandra A, Cross P, et al. BSCC code of practice - fine needle aspiration cytology. Cytopathology. 2009;20(5):283-296. https://doi.org/10.1111/j.1365-2303.2009.00709.x
8. Ljung B-M. Thyroid fine-needle aspiration: Smears versus liquid-based preparations. Cancer. 2008;114(3):144-148. https://doi.org/10.1002/cncr.23541
9. Biscotti CV, Hollow JA, Teddy SM, Easley KA. ThinPrep versus conventional smear cytologic preparations in the analysis of thyroid fine-needle aspiration specimens. Am J Clin Pathol. 1995;104(2):150-153. https://doi.org/10.1093/ajcp/104.2.150
10. Fischer AH, Clayton AC, Bentz JS, et al. Performance differences between conventional smears and liquid-based preparations of thyroid fine-needle aspiration samples: analysis of 47 067 responses in the college of american pathologists interlaboratory comparison program in non-gynecologic cytologic. Arch Pathol Lab Med. 2013;137(1):26-31. https://doi.org/10.5858/arpa.2012-0099-CP
11. Afify AM, Liu J, Al-Khafaji BM. Cytologic artifacts and pitfalls of thyroid fine-needle aspiration using ThinPrep®: A comparative retrospective review. Cancer. 2001;93(3):179-186. https://doi.org/10.1002/cncr.9027
12. Livingstone E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. https://doi.org/10.1001/jama.2020.4344
13. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523. https://doi.org/10.1016/S0140-6736(20)30154-9
14. Barbareschi M, Ascoli V, Bonoldi E, et al. DOCUMENTO SIAPEC-IAP: Gestione del rischio biologico correlato alla epidemia di COVID-19 nella manipolazione dei campioni tissutali e citologici, con particolare riguardo ai campioni a fresco o non adeguatamente fissati. Published 2020. https://www.siapec.it/public/uploads/archiviodocumenti/Biosicurezza-In-anat-pat-25-marzo-20-3.pdf
15. CDC. Centre for Disease control and Prevention. Laboratory biosafety guidelines for handling and processing specimens associated with SARS-CoV. https://www.cdc.gov/sars/guidance/f-lab/app5.html. Cdc. Published online 2004:2003-2005. https://www.cdc.gov/sars/survveillance/absence.pdf
16. WHO. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). Interim Guid. 2020;2019:1-13. https://apps.who.int/iris/bitstream/handle/10665/331138/WHO-WPE-GIH-2020.1-eng.pdf
17. Henwood AF. Coronavirus disinfection in histopathology. J Histotechnol. 2020;43(2):102-104. https://doi.org/10.1080/0147885.2020.1734718
18. Darnell MER, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion. 2006;46(10):1770-1777. https://doi.org/10.1111/j.1537-2995.2006.00976.x
19. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
20. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411-412. https://doi.org/10.1016/S1473-3099(20)30113-4
21. Guerini-Rocco E, Taormina SV, Vacirca D, et al. SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma. J Clin Pathol. 2020;73(11):754-757. https://doi.org/10.1136/jclinpath-2020-206635
22. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016;92(3):235-250. https://doi.org/10.1016/j.jhin.2015.08.027
23. Marqués M, Domingo JL. Contamination of inert surfaces by SARS-CoV-2: persistence, stability and infectivity. A review. Environ Res. 2021;193:e110559. https://doi.org/10.1016/j.envres.2020.110559
24. Nardi F, Basolo F, Crescenzi A, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37(6):593-599. https://doi.org/10.1007/s40618-014-0062-0
25. Weid GL, Bibbo M, Keebler CM, Koss LG, Patten SMRD. Tutorials of Cytology, International Academy of Cytology. Int Acad Cytol Chicago. Published online 1992.
26. Chong Y, Ji SJ, Kang CS, Lee EJ. Can liquid-based preparation substitute for conventional smear in thyroid fine-needle aspiration? A systematic review based on meta-analysis. Endocr Connect. 2017;6(8):817-829. https://doi.org/10.1530/EC-17-0165
27. Fadda G, Rossi ED. Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol. 2011;55(5):389-400. https://doi.org/10.1159/000329029
28. Hutchinson ML, Cassin CM, Ball HG. The efficacy of an automated preparation device for cervical cytology. Am J Clin Pathol. 1991;96(3):300-305. https://doi.org/10.1093/ajcp/96.3.300
29. Straccia P, Rossi ED, Martini M, et al. Description of a new biosafe procedure for cytological specimens from patients with COVID-19 processed by liquid-based preparations. Cancer Cytopathol. 2020;128(12):905-909. https://doi.org/10.1002/cncy.22341
30. Fallahi P, Giannini R, Miccoli P, Antonelli A, Basolo F. Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. Curr Genomics. 2014;15(3):171-177. https://doi.org/10.2174/1389202915999140404100347
31. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. *J Clin Endocrinol Metab.* 2009;94(6):2092-2098. https://doi.org/10.1210/jc.2009-0247

32. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. *J Clin Endocrinol Metab.* 2010;95(3):1365-1369. https://doi.org/10.1210/jc.2009-2103

How to cite this article: Rossi D, Belotti A, di Tonno C, et al. Changes in thyroid fine needle aspiration practice during the COVID-19 pandemic. *Cytopathology.* 2021;00:1–6. https://doi.org/10.1111/cyt.13020